recentpopularlog in

PieroRivizzigno : healthcare   788

« earlier  
Blinding and Patient-Reported Outcome Completion Rates in US Food and Drug Administration Cancer Trial Submissions, 2007–2017 | JNCI: Journal of the National Cancer Institute | Oxford Academic
Patient-reported outcomes (PROs) are commonly included in submissions to the United States Food and Drug Administration (FDA). Open-label designs are frequent in cancer trials. Between-arm differences in PRO missingness may affect results. We sought to compare PRO completion rates between study arms in randomized open-label and double-blind cancer trials.
PRO  meta-analysis  healthcare 
2 days ago by PieroRivizzigno
Is precision medicine really the best approach to improving health? - STAT
wenty years ago, Dr. Francis Collins, who was then director of the National Center for Human Genome Research, made rosy predictions in his Shattuck Lecture about the health benefits sure to flow from the Human Genome Project. His paper on the lecture, “Medical and Societal Consequences of the Human Genome Project,” published in the New England Journal of Medicine, provided an early template for the precision medicine narrative of the past two decades.
healthcare  precision-medicine  counterpoint 
11 days ago by PieroRivizzigno
Making New Drugs With a Dose of Artificial Intelligence
The contest, the Critical Assessment of Structure Prediction, was not won by academics. It was won by DeepMind, the artificial intelligence lab owned by Google’s parent company.

“I was surprised and deflated,” said Dr. AlQuraishi, a researcher at Harvard Medical School. “They were way out in front of everyone else.”
neural-network  DeepMind  drug-development  healthcare 
11 days ago by PieroRivizzigno
Hard Lessons For Would-Be Healthcare Innovators From UCSF Expert
Keystone meetings are, by design, off the record, in effort to stimulate the free exchange of pre-publication information among participants; however, I’m going to talk about one of the presentations, by UCSF professor Dr. Aenor Sawyer, with her explicit permission.
healthcare  von-hippel  transformation  Innovation 
16 days ago by PieroRivizzigno
Real-world studies no substitute for RCTs in establishing efficacy - The Lancet
We live in the real world, so it is reasonable to expect that data collected from the real world should help identify effective therapies. Indeed, rapid increases in the availability of registries, electronic health records, and insurance claims, and the ability to access, process, link, and analyse data from these sources at fairly low cost lend support for calls to replace randomised controlled trials (RCTs) with so-called real-world studies to establish the efficacy of a therapy, 1
healthcare  RWE  RCT 
17 days ago by PieroRivizzigno
Pre‐operative nutrition and the elective surgical patient: why, how and what? - Gillis - 2019 - Anaesthesia - Wiley Online Library
Pre‐operative nutrition therapy is increasingly recognised as an essential component of surgical care. The present review has been formatted using Simon Sinek's Golden Circle approach to explain ‘why’ avoiding pre‐operative malnutrition and supporting protein anabolism are important goals for the elective surgical patient, ‘how’ peri‐operative malnutrition develops leading in part to a requirement for pre‐operative anabolic preparation, and ‘what’ can be done to avoid pre‐operative malnutrition and support anabolism for optimal recovery.
healthcare  nutrition  pre-operative 
17 days ago by PieroRivizzigno
Carbohydrate quality and human health: a series of systematic reviews and meta-analyses - The Lancet
Previous systematic reviews and meta-analyses explaining the relationship between carbohydrate quality and health have usually examined a single marker and a limited number of clinical outcomes. We aimed to more precisely quantify the predictive potential of several markers, to determine which markers are most useful, and to establish an evidence base for quantitative recommendations for intakes of dietary fibre.
healthcare  nutrition  met-analysis 
17 days ago by PieroRivizzigno
The GENERATE Study | GENetic Education, Risk Assessment, and TEsting
Help GENERATE’s world-class pancreatic cancer experts make a difference in cancer care.

GENERATE will begin enrolling in early 2019. Please fill out our contact form, and we’ll be in touch when enrollment starts.
healthcare  cancer  pancreas  screening  GENERATE 
17 days ago by PieroRivizzigno
Meeting Library | The need for improvement in the management of fatigue, depression and pain in pancreatic cancer.
Pancreatic cancer (PC) and its treatment(s) results in symptom and side effect burden and can impact patient’s overall quality of life (QOL).
healthcare  cancer  quality-of-life  QoL 
18 days ago by PieroRivizzigno
When is crossover desirable in cancer drug trials and when is it problematic? | Annals of Oncology | Oxford Academic
The use of crossover, as a design feature of randomized trials, is common, with reports indicating that up to 22% of all randomized controlled trials utilize this feature
healthcare  crossover  clinical-trial 
20 days ago by PieroRivizzigno
McCain is called a warrior. Is that the right metaphor for fighting cancer?
he metaphor was inevitable.

Moments after the news of Sen. John McCain’s brain tumor reached the internet, he was being pinned with the badge of the cancer warrior.
Healthcare  cancer  psychology 
22 days ago by PieroRivizzigno
Be More Sensitive to the Toxicities of Cancer Therapy | Page 1
It is difficult to overstate the magnitude of the transformation in cancer management over the past several decades. Any short list of the most impactful events during this extended period must include advances in antineoplastic drug delivery.
healthcare  cancer  symptoms  toxicity 
23 days ago by PieroRivizzigno
Drug companies paid $116 million to patient advocacy groups in 2015 alone, new data suggests | PBS NewsHour
Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database logging 12,000 donations from large publicly traded drugmakers to such organizations.
healthcare  associazioni  COI 
23 days ago by PieroRivizzigno
Meeting Library | Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program.
Advanced DDRmut pts have an improved OS when treated with platinums, compared to pDDR pts. But, in the absence of platinum-based therapy, there is no OS difference observed in DDRmut vs. pDDR pts, suggesting that DDR status has no pure prognostic value. These findings support the need to test all pts with advanced PDA, to ensure that DDRmut pts are treated with platinum-based therapy.
healthcare  cancer  pancreas  DNA-repair  genetics  platinum  therapy 
23 days ago by PieroRivizzigno
Opinion | Dr. Google Is a Liar - The New York Times
Fake news threatens our democracy. Fake medical news threatens our lives.
healthcare  Google  fake-news 
26 days ago by PieroRivizzigno
Pancreatic cancer | Guidance and guidelines | NICE
This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.
healthcare  cancer  pancreas  NICE  multidisciplinary  standard 
26 days ago by PieroRivizzigno
VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance | MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center research team found overexpression of the immune checkpoint VISTA on immune cells, especially macrophages, that infiltrated pancreatic tumors. Their paper will be published online Friday at the Proceedings of the National Academy of Sciences.
healthcare  cancer  pancreas  VISTA  MD-Anderson 
26 days ago by PieroRivizzigno
The Race to Diagnose Cancer With a Simple Blood Test
ive years ago, a team of researchers pored over the results of a prenatal genetic test given to more than 125,000 healthy pregnant women and made a stunning discovery. The blood test, marketed by gene-sequencing giant Illumina, was designed to detect chromosome anomalies associated with conditions such as Down syndrome by analyzing fragments of fetal DNA circulating in the mother’s blood.
healthcare  cancer  test 
26 days ago by PieroRivizzigno
Single Blood Test Screens for Eight Cancer Types
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. The test is aimed at screening for eight common cancer types that account for more than 60 percent of cancer deaths in the U.S. Five of the cancers covered by the test currently have no screening test.
healthcare  cancer  test  CancerSEEK 
26 days ago by PieroRivizzigno
Why We Revolt — The Patient Revolution
Our mission is to arm people to tell stories; stories about their lives, stories about their capabilities and limitations, and stories about what risks, benefits and trade-offs look like from their point of view. We want people to tell these stories in exam rooms and hospital rooms, in their communities and in the rooms where decisions get made.
Book  healthcare  patient 
26 days ago by PieroRivizzigno
What happened when biotech startup pursued a new treatment for pancreatic cancer. - The Washington Post
Two years ago, as a Harvard undergraduate, I started a biotech company with a fellow student to develop an experimental drug for pancreatic cancer.

As biology majors, we had read a paper by a Harvard Medical School professor about an intriguing experiment and hoped we had found a possible solution to one of the world’s most lethal diseases. Rather than try to kill pancreatic tumors directly, we would block a cellular system called Hippo-YAP, which shields cancer from existing cancer-killing drugs. According to the paper, drugs that had been ineffective successfully destroyed pancreatic tumors in mice after Hippo-YAP was inactivated.
healthcare  cancer  pancreas  drug-development  failure 
5 weeks ago by PieroRivizzigno
Commentary: Oncologist speaks out on human toll of high health care costs
A Fred Hutch researcher speaks out on the human cost of the ‘unfettered, unbridled greed’ within our health care system
healthcare  cancer  financial-toxicity  greediness  COI 
5 weeks ago by PieroRivizzigno
False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care | Genetics in Medicine
There is increasing demand from the public for direct-to-consumer (DTC) genetic tests, and the US Food and Drug Administration limits the type of health-related claims DTC tests can market.
counterpoint  healthcare  genetic-testing  false-positive 
7 weeks ago by PieroRivizzigno
Commentary: Patients As Partners At San Antonio Breast Cancer Symposium : Shots - Health News : NPR
Another thing that makes the symposium special is the presence of a couple of hundred patient advocates alongside scientists and clinicians. In San Antonio, advocates stand up and ask questions after plenary talks. Patients sit on panels, contribute papers and weigh in on research priorities
healthcare  cancer  patient  advocacy 
7 weeks ago by PieroRivizzigno
The cancer stories no one wants to hear - STAT
uring the 11 months when my husband, Ahmad, was dying of bladder cancer, few people wanted to hear how he was truly doing. They wanted to hear about hope, courage, and positivity, not about how Ahmad was unlikely to survive or his ruminations on how to live well while dying.
healthcare  patient  story  war  metastatic  counterpoint  psychology 
7 weeks ago by PieroRivizzigno
Press Announcements > FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
This is the first approval that FDA has granted as a part of two new pilot programs announced earlier this year that collectively aim to make the development and review of cancer drugs more efficient, while improving FDA’s rigorous standard for evaluating efficacy and safety.
new  clinical-trial  approval-process  healthcare 
7 weeks ago by PieroRivizzigno
Surgery unnecessary for many prostate cancer patients. ecancer - News
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it.
healthcare  surgery  cancer  prostate 
8 weeks ago by PieroRivizzigno
Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance | JCO Precision Oncology
Randomized clinical trials (RCTs) are the gold standard for rational therapeutics in evidence-based medicine.1 Although variable, the cost of conducting an RCT can be as high as $1 billion,1 putting into question their feasibility for every health care intervention. Also, the broader application of RCT outcomes has been subject to scrutiny, considering the inherent selection bias. Less than 5% of adult patients with cancer participate in clinical trials, and those who do are younger, healthier, and less diverse than their real-world counterparts.2 Today, RCTs remain the gold standard despite changing practice patterns; however, because of their limitations, coupled with unmet health care needs, a reassessment of whether this traditional approach should be required for low-risk interventions, particularly in cancer, is warranted.
healthcare  RCT  RWE  PRO 
10 weeks ago by PieroRivizzigno
Patient involvement toolkit for researchers | Cancer Research UK
Patient involvement can improve the quality and relevance of your work, helping you better understand and articulate the benefits your research can have for cancer patients. 

This toolkit provides guidance, tips and templates to help you plan, deliver and evaluate your patient involvement. Once you’ve planned how you want to involve patients, we can also help you find them. 
healthcare  patient-engagement  toolkit  UK 
11 weeks ago by PieroRivizzigno
Statistical pitfalls of personalized medicine
Misleading terminology and arbitrary divisions stymie drug trials and can give false hope about the potential of tailoring drugs to individuals, warns Stephen Senn
healthcare  precision-medicine  counterpoint 
11 weeks ago by PieroRivizzigno
Researchers Explore a Cancer Paradox - The New York Times
Healthy cells carry a surprising number of cancer-linked mutations, but they don’t turn into tumors. What’s holding them back?
cancer  Cell  mutations  healthcare  counterpoint  growth 
november 2018 by PieroRivizzigno
Editor’s letter: The precision medicine issue
Precision medicine has led to incredibly effective treatments for cancer and inherited disease. But not everyone gets treated.
healthcare  MIT  precision-medicine 
november 2018 by PieroRivizzigno
A systematic literature review of individuals’ perspectives on privacy and genetic information in the United States
Concerns about genetic privacy affect individuals’ willingness to accept genetic testing in clinical care and to participate in genomics research.
healthcare  privacy  genetics 
november 2018 by PieroRivizzigno
Why Doctors Hate Their Computers
Digitization promises to make medical care easier and more efficient. But are screens coming between doctors and patients?
healthcare  digital-health  digital-culture  doctor  computer-aversion 
november 2018 by PieroRivizzigno
U.S. Cancer Centers Deceptive Testimonials Database | Truth In Advertising conducted a review of patient testimonials used to promote the 50 cancer treatment centers in the U.S. that spent the most money on advertising in 2017. Our results revealed that, of the cancer centers still in business in 2018, 43 out of 48 – or 90% – deceptively used patient testimonials in their marketing materials by promoting anecdotal, atypical patient results without clearly and conspicuously disclosing what the generally expected results for a patient in a similar situation would be.
healthcare  deception  Advertising 
november 2018 by PieroRivizzigno
Science & Research (Drugs) > FDA’s MyStudies Application (App)
The U.S. Food and Drug Administration (FDA) is posting computer code and a technical roadmap that will allow researchers and developers to customize and use the FDA’s newly created MyStudies app. The FDA MyStudies App is designed to facilitate the input of real world data directly by patients which can be linked to electronic health data supporting traditional clinical trials, pragmatic trials, observational studies and registries
healthcare  digital-health  app  FDA  MyStudies 
november 2018 by PieroRivizzigno
Decentralized clinical trials – Andrea’s Blog
A framework for “direct-to-patient,” “remote,” “site-less,” and “virtual” clinical research
healthcare  digital-health  trial  decentralized 
october 2018 by PieroRivizzigno
Google AI Blog: Applying Deep Learning to Metastatic Breast Cancer Detection
A pathologist’s microscopic examination of a tumor in patients is considered the gold standard for cancer diagnosis, and has a profound impact on prognosis and treatment decisions. One important but laborious aspect of the pathologic review involves detecting cancer that has spread (metastasized) from the primary site to nearby lymph nodes. Detection of nodal metastasis is relevant for most cancers, and forms one of the foundations of the widely-used TNM cancer staging.
healthcare  digital-health  breast-cancer  diagnosis  deep-learning  Google 
october 2018 by PieroRivizzigno
A Cancer Patient’s Guide to Clinical Trials — ProPublica
If you’re considering whether to enroll in a trial of an experimental drug, here’s what you need to know.
healthcare  trial  patient 
october 2018 by PieroRivizzigno
The market trend analysis and prospects of cancer molecular diagnostics kits | Biomaterials Research | Full Text
The molecular diagnostics market can be broadly divided into PCR (rt-PCR, d-PCR), NGS(Next Generation Sequencing), Microarray, FISH(Fluorescent in situ-hybridization) and other categories, based on the diagnostic technique. Also, depending on the disease being diagnosed, the market can also be divided into cancer, infectious diseases, HIV/STDs (herpes, syphilis), and women’s health issues such as breast cancer, cervical cancer, ovarian cancer, HPV(human papillomavirus), and vaginitis.
healthcare  molecular-diagnostic  market-size 
september 2018 by PieroRivizzigno
Frontiers | The Potential of CAR T Cell Therapy in Pancreatic Cancer | Immunology
This review summarizes the available preclinical data and highlights early phase clinical trials using CAR T cell approaches in pancreatic cancer, a disease state that is gaining attention as a conduit for cell therapy. Future directions in application of CAR T cell therapy are also considered including its ability to be directed against novel epitopes and combined with other therapeutic regimens.
healthcare  cancer  pancreas  CAR-T  immunotherapy 
september 2018 by PieroRivizzigno
A Run of Contrary Results | In the Pipeline
From the outside, medical progress looks a lot easier than it really is. Well, I realize that’s true of a lot of things, but it’s especially true in progress against disease, and that’s especially especially true (as I’ve said here before) when you’re talking about dietary influences and what can be learned from them. Butter, whole milk, and other dairy products – bad for your cardiovascular health, right? Not according to this new observational study of 136,000 people across 21 countries.
healthcare  nutrition  counterpoint 
september 2018 by PieroRivizzigno
(38) Pancreatic Cancer: Advances in Science and Clinical Care - YouTube
This AACR Special Conference, to be held September 21-24, 2018, in Boston, will convene world-renowned experts covering the breadth of research on pancreatic cancer, from early detection and genetics to precision medicine and immunotherapy.
healthcare  cancer  pancreas  AACR  state-of-art 
september 2018 by PieroRivizzigno
21st Century Physician: Triaging the Tsunami of Medical Information
I am occasionally asked for advice on keeping up with the tsunami of medical information while separating facts from spin. Here are my tips.
healthcare  how-to-read 
september 2018 by PieroRivizzigno
Genetic determinism rides again
And yet, here we are again with Blueprint, by educational psychologist Robert Plomin. Although Plomin frequently uses more civil, progressive language than did his predecessors, the book’s message is vintage genetic determinism: “DNA isn’t all that matters but it matters more than everything else put together”. “Nice parents have nice children because they are all nice genetically.” And it’s not just any nucleic acid that matters; it is human chromosomal DNA. Sorry, microbiologists, epigeneticists, RNA experts, developmental biologists: you’re not part of Plomin’s picture.
healthcare  genetics  determinism  reductionism 
september 2018 by PieroRivizzigno
How one pharmaceutical company is reinventing the clinical trial - STAT
Clinical trials are as essential today as drug discovery for bringing new drugs to market. But while new tools and technologies have helped advance techniques for new drug discovery, we’ve seen far less innovation in clinical trials. The process continues to be weighed down with regulatory paperwork, medical jargon, and participants’ time-intensive trips to trial sites.
healthcare  clinical-trial  trial  Jansen  Scripps  digital-health 
september 2018 by PieroRivizzigno
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar - The New York Times
The company, Paige.AI, is one in a burgeoning field of start-ups that are applying artificial intelligence to health care, yet it has an advantage over many competitors: The company has an exclusive deal to use the cancer center’s vast archive of 25 million patient tissue slides, along with decades of work by its world-renowned pathologists.
healthcare  pathology  Memorial-Sloan-Kettering-Cabcer-Center  cancer  conflict-of-interest 
september 2018 by PieroRivizzigno
Everyday Sociology Blog: A Sociology of My Death
I’m dying. I don’t mean this figuratively—like I’m dying of thirst or dying to visit Hawaii. I mean it quite literally. I have incurable, stage IV lung cancer.
healthcare  sociology  death 
september 2018 by PieroRivizzigno
Cancer treatment in the last 6 months of life: when inaction can outperform action. ecancermedicalscience - The open access journal from the European Institute of Oncology and the OCEI
For example, when a patient’s life expectancy is less than 6 months, many oncologists will not embark on any active cancer treatments. However, multiple new anticancer drugs have been approved recently after being tested in end-stage cancer patients and demonstrating median OS in the experimental arm close to 6 months. Such practice, particularly when the treatment is also accompanied by serious toxicities and cost, can undermine a peaceful life-death transition.
cancer  ethics  healthcare  end-of-life 
september 2018 by PieroRivizzigno
TechCrunch - Disrupt SF 2018 | Anne Wojcicki (23andMe) | Facebook
23andMe CEO Anne Wojcicki on the tremendous opportunities that can be unlocked by genetic testing
healthcare  cancer  precision-medicine  23andme  interview  video 
september 2018 by PieroRivizzigno
(30) Understanding Nutrition and the Role and Benefits of PERT - YouTube
This animation describes pancreatic enzyme replacement therapy (PERT) and it’s role and benefit for patients who have exocrine pancreatic insufficiency (EPI). The animation provides an overview of the role of pancreatic enzymes in food digestion, the different types of PERT medications that are currently available, and provides tips for dosing and timing of PERT. For the majority of patients taking PERT, there is a significant improvement of symptoms, nutritional status, and overall quality of life.
Visit to learn more.
healthcare  cancer  pancreas  nutrition  enzymes 
september 2018 by PieroRivizzigno
OncoKB: A Precision Oncology Knowledge Base | JCO Precision Oncology
With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base.
healthcare  cancer  precision-medicine  OncoKB  SMKC 
september 2018 by PieroRivizzigno
Neuroendocrine Cancer and Pancreatic Enzyme Replacement Therapy (PERT) – the Digested Version (Nutrition Series Article 5) – Ronny Allan – Living with Neuroendocrine Cancer
We eat food, but our digestive system doesn’t absorb food, it absorbs nutrients. Food has to be broken down from things like steak and broccoli into its nutrient pieces: amino acids (from proteins), fatty acids and cholesterol (from fats), and simple sugars (from carbohydrates), as well as vitamins, minerals, and a variety of other plant and animal compounds. Digestive enzymes, primarily produced in the pancreas and small intestine, break down our food into nutrients so that our bodies can absorb them.
healthcare  cancer  pancreas  nutrition  enzymes  Allan  reference 
september 2018 by PieroRivizzigno
Palliative Care in Metastatic Pancreatic Cancer
Panelists: John L. Marshall, MD, Georgetown University; George Kim, MD, 21st Century Oncology; Kabir Mody, MD, Mayo Clinic Cancer Center; Eileen M. O
Published: Monday, Aug 27, 2018
healthcare  cancer  pancreas  palliative  care 
september 2018 by PieroRivizzigno
Patient Checklist - Lustgarten Foundation: Pancreatic Cancer Research
As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis.
healthcare  cancer  pancreas  checklist  Lustgarten 
september 2018 by PieroRivizzigno
All study participants have a right to know their own results- STAT
Between the rise in direct-to-consumer products and more transparent medical care, people today have access to myriad types of data about their personal health — and they’ve come to expect it. Yet for participants in most research studies, outdated ethical standards prevent them from learning anything at all about what was found in their blood, urine, or any other tissue they donated for research.
healthcare  trial  data  patient  transparency 
september 2018 by PieroRivizzigno
Estimation of the Acquisition and Operating Costs for Robotic Surgery | Minimally Invasive Surgery | JAMA | JAMA Network
Despite evidence questioning the clinical benefit,1 the use of the robotic platform for surgical procedures is increasing.2 No benchmark exists for the cost of acquiring and operating robotic systems, and previous cost evaluations have either omitted key expenses1 or utilized billing records that do not itemize costs with sufficient granularity.2
healthcare  surgery  robotics  cost 
september 2018 by PieroRivizzigno
Dynamic Behavior of Ca 19-9 and Pancreatic Cancer Recurrence: Enough Data to Drive Salvage Therapy? | SpringerLink
Up to 80% of patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) followed by adjuvant therapy will recur within 2 years, with median recurrence-free survival (RFS) of only 1 year.1
healthcare  cancer  pancreas  surgery  CA-19.9  Verona 
september 2018 by PieroRivizzigno
The paradox of precision medicine | Nature Reviews Clinical Oncology
According to the paradigm of precision medicine, the administration of agents targeting the molecular alteration detected in a particular patient’s tumour reduces uncertainty in the clinical management of that patient. We describe how approaches to precision medicine can lead, paradoxically, to increased levels of uncertainty. We offer recommendations for how physicians can better navigate new uncertainties in precision medicine.
healthcare  cancer  precision-medicine  counterpoint 
september 2018 by PieroRivizzigno
Opinion | Are We Being Misled About Precision Medicine? - The New York Times
Doctors and hospitals love to talk about the cancer patients they’ve saved, and reporters love to write about them. But deaths still vastly outnumber the rare successes.
healthcare  cancer  precision-medicine  counterpoint 
september 2018 by PieroRivizzigno
Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement: Journal of Clinical Oncology: Vol 0, No 0
Research conducted through clinical trials is essential for evaluating new treatment modalities, establishing new standards of cancer care, and ultimately improving and prolonging the lives of patients with cancer. However, participation in trials has been low, and this is attributable to various factors including patient financial barriers.
healthcare  trial  patient  participation  barriers  financial 
september 2018 by PieroRivizzigno
« earlier      
per page:    204080120160

Copy this bookmark:

to read